<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>S$^2$Drug: Bridging Protein Sequence and 3D Structure in Contrastive Representation Learning for Virtual Screening - Health AI Hub</title>
    <meta name="description" content="S$^2$Drug is a novel two-stage deep learning framework designed to improve virtual screening in drug discovery by explicitly bridging protein sequence informati">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>S$^2$Drug: Bridging Protein Sequence and 3D Structure in Contrastive Representation Learning for Virtual Screening</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.07006v1" target="_blank">2511.07006v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-10
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Bowei He, Bowen Gao, Yankai Chen, Yanyan Lan, Chen Ma, Philip S. Yu, Ya-Qin Zhang, Wei-Ying Ma
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.07006v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.07006v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">S$^2$Drug is a novel two-stage deep learning framework designed to improve virtual screening in drug discovery by explicitly bridging protein sequence information and 3D structural context. It addresses limitations of existing methods that primarily rely on structural data, achieving enhanced performance by combining sequence pretraining with structure-sequence fusion and an auxiliary binding site prediction task.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research significantly enhances the efficiency and accuracy of virtual screening, a critical step in drug discovery. By improving the identification of potential small-molecule ligands for specific protein targets, S$^2$Drug can accelerate the development of new therapeutics and personalized medicines.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This AI method (S^2Drug) significantly improves the accuracy and efficiency of virtual screening, a key process in drug discovery. By better predicting how small-molecule ligands bind to specific protein targets and localizing binding sites, it accelerates the identification of potential new drug candidates. This directly supports the development of novel therapeutics for various diseases, making the drug discovery pipeline faster and potentially more cost-effective through advanced AI algorithms.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the limitation of existing deep learning virtual screening (VS) methods that primarily rely on 3D structural data while overlooking more accessible protein sequence information.</li>
                    
                    <li>Proposes S$^2$Drug, a two-stage framework for protein-ligand contrastive representation learning that integrates both protein sequence and 3D structure.</li>
                    
                    <li>The first stage involves protein sequence pretraining on ChemBL using an ESM2-based backbone, employing a tailored data sampling strategy to reduce redundancy and noise in the protein and ligand datasets.</li>
                    
                    <li>The second stage fine-tunes the model on PDBBind by fusing sequence and structure information through a residue-level gating module.</li>
                    
                    <li>Introduces an auxiliary binding site prediction task during the fine-tuning stage to guide the model in accurately localizing binding residues within the protein sequence and capturing their 3D spatial arrangement, thereby refining protein-ligand matching.</li>
                    
                    <li>S$^2$Drug consistently improves virtual screening performance across multiple benchmarks compared to existing methods.</li>
                    
                    <li>Achieves strong results on the auxiliary binding site prediction task, validating its ability to effectively identify critical binding regions and integrate multi-modal information.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>S$^2$Drug is a two-stage deep learning framework. The first stage involves protein sequence pretraining on the ChemBL database, leveraging an ESM2-based backbone and a specialized data sampling strategy to mitigate redundancy and noise. The second stage fine-tunes the pretrained model on PDBBind, integrating protein sequence and 3D structure data via a novel residue-level gating module. An auxiliary binding site prediction task is incorporated during fine-tuning to guide the model in identifying and spatially arranging key binding residues, thereby refining protein-ligand matching.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>S$^2$Drug consistently demonstrates improved virtual screening performance across various benchmarks. Furthermore, the model achieves strong results in the auxiliary binding site prediction task, confirming its capability to accurately localize binding residues and effectively bridge protein sequence and 3D structural information.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The enhanced accuracy and generalizability in virtual screening provided by S$^2$Drug can significantly streamline the early phases of drug discovery. This could lead to a faster and more cost-effective identification of promising drug candidates, potentially reducing the time and resources needed to bring new and more effective treatments to patients across various disease areas.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state specific limitations of the S$^2$Drug framework itself. It rather highlights the challenges in existing deep learning methods (reliance on structural data, redundancy/noise in large datasets) that S$^2$Drug aims to overcome.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly mention future research directions for S$^2$Drug.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Structural Biology</span>
                    
                    <span class="tag">Drug Discovery and Development</span>
                    
                    <span class="tag">Bioinformatics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Virtual Screening</span>
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Protein-Ligand Interaction</span>
                    
                    <span class="tag tag-keyword">Protein Sequence</span>
                    
                    <span class="tag tag-keyword">3D Structure</span>
                    
                    <span class="tag tag-keyword">Contrastive Learning</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">Binding Site Prediction</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Virtual screening (VS) is an essential task in drug discovery, focusing on
the identification of small-molecule ligands that bind to specific protein
pockets. Existing deep learning methods, from early regression models to recent
contrastive learning approaches, primarily rely on structural data while
overlooking protein sequences, which are more accessible and can enhance
generalizability. However, directly integrating protein sequences poses
challenges due to the redundancy and noise in large-scale protein-ligand
datasets. To address these limitations, we propose \textbf{S$^2$Drug}, a
two-stage framework that explicitly incorporates protein \textbf{S}equence
information and 3D \textbf{S}tructure context in protein-ligand contrastive
representation learning. In the first stage, we perform protein sequence
pretraining on ChemBL using an ESM2-based backbone, combined with a tailored
data sampling strategy to reduce redundancy and noise on both protein and
ligand sides. In the second stage, we fine-tune on PDBBind by fusing sequence
and structure information through a residue-level gating module, while
introducing an auxiliary binding site prediction task. This auxiliary task
guides the model to accurately localize binding residues within the protein
sequence and capture their 3D spatial arrangement, thereby refining
protein-ligand matching. Across multiple benchmarks, S$^2$Drug consistently
improves virtual screening performance and achieves strong results on binding
site prediction, demonstrating the value of bridging sequence and structure in
contrastive learning.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>Accepted by AAAI 2026 Main Technical Track</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>